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Alpha-Mannosidase-II Deficiency Results in
Dyserythropoiesis and Unveils an Alternate
Pathway in Oligosaccharide Biosynthesis
Daniel Chui,* Masayoshi Oh-Eda,² Yung-Feng Liao,³ Swainsona (Elbein et al., 1981; Tulsiani et al., 1982).
Krishnasamy Panneerselvam,² Anita Lal,³ Ingestion by vertebrates produces a disease known as
Kurt W. Marek,* Hudson H. Freeze,² ªlocoism,º biochemically similar to a-mannosidosis and
Kelley W. Moremen,³ Michiko N. Fukuda,² associated with aberrant behavior, male sterility, cyto-
and Jamey D. Marth* plasmic vacuolation, and the accumulation of hybrid
*Howard Hughes Medical Institute N-glycans in the brain and other tissues (Dorling et al.,
and Division of Cellular and Molecular Medicine 1978; Colgate et al., 1979; Tulisani et al., 1988). In animal
University of California San Diego studies with the purified alkaloid, theeffects of locoweed
La Jolla, California 92093 ingestion appear to be due to swainsonine (Tulsiani et
²The Burnham Institute al., 1984, 1988). However, a role for aM-II deficiency in
10901 North Torrey Pines Road these responses is not clear, since swainsonine is also a
La Jolla, California 92037 potent inhibitor of the lysosomal a-mannosidase, which
³Department of Biochemistry functions in N-glycan catabolism (Dorling et al., 1980;
University of Georgia Tulsiani et al., 1982; Tulsiani and Touster, 1987).
Athens, Georgia 30602 Human deficiency of aM-II has been reported in one
case of congenital dyserythropoietic anemia (CDA) type
II, also known as HEMPAS (hereditary erythroblastic
Summary multinuclearity with a positive acidified serum-lysis test)
disease (Crookston et al., 1969; Fukuda et al., 1990).
Alpha-mannosidase-II (aM-II) catalyzes the first com- CDA type II/HEMPAS is inherited in an autosomal reces-
mitted stepin thebiosynthesis of complex asparagine- sive manner, with patients developing mild-to-severe
linked (N-linked) oligosaccharides (N-glycans). Ge- anemia associated with splenomegaly and marrow
netic deficiency of aM-II should abolish complex erythroplasia in the presence of multinucleated erythro-
N-glycan production as reportedly does inhibition of blasts (reviewed in Fukuda, 1993). Most patients live a
aM-II by swainsonine. We find that mice lacking a normal lifespan without neurologic involvement, al-
functional aM-II gene develop a dyserythropoietic though complications, including hepatomegaly with cir-
anemia concurrent with loss of erythrocyte complex rhosis, hemosiderosis, gallstones, and diabetes, fre-
N-glycans. Unexpectedly, nonerythroid cell types con- quently develop. CDA type II erythrocytes commonly
tinued to produce complex N-glycans by an alternate exhibit plasma membrane abnormalities with loss of
pathway comprising a distinct a-mannosidase. These complex N-linked oligosaccharides from glycoproteins
studies reveal cell-type-specific variations in N-linked band 3 (AE1) and band 4.5 (GLUT1) (Baines et al., 1982;
oligosaccharide biosynthesis and an essential role for
Scartezzini et al., 1982; Fukuda et al., 1984, 1992). How-
aM-II in the formation of erythroid complex N-glycans.
ever, the clinical diagnosis of CDA type II encompasses
aM-II deficiency elicits a phenotype in mice that corre-
heterogenic symptomswith only one reported case thuslates with human congenital dyserythropoietic anemia
far associated with aM-II deficiency, in which the patienttype II.
retained only 10% of normal aM-II levels with an unre-
solved genetic defect.
Introduction The biological role of aM-II is further puzzling, consid-
ering its pivotal position in complex N-glycan production
Vertebrate cell surfaces are covered with a diverse and
and the relatively mild phenotype of CDA type II when
dynamic repertoire of asparagine-linked (N-linked) oli-
compared to GlcNAc-TII deficiency in the next biosyn-
gosaccharides (also termed N-glycans, indicating link-
thetic step. Studies have linked inactivating mutationsage to underlying protein). Complex N-glycans are the
in the MGAT2 gene to human carbohydrate-deficientmost abundant type found on the cell surface, and
glycoprotein syndrome (CDGS) type II (Tan et al., 1996).alpha-mannosidase-II (aM-II) acts as a key enzyme in
This autosomal recessive disease presents severetheir biosynthesis by catalyzing the first committed step
symptoms early with children exhibiting failure to thrive,in the conversion of hybrid to complex forms (Kornfeld
dysmorphic features, severe mental retardation, andand Kornfeld, 1985; Schachter, 1991; Figure 1). In the
susceptibilty to multiple infections (Jaeken et al., 1994;Golgi apparatus, aM-II cleaves two mannose residues
Charuk et al., 1995). In order to understand how aM-attached in a3 and a6 linkages from the hybrid N-glycan
II functions in mammalian physiology and in N-glycanGlcNAc1Man5GlcNAc2-Asn, thereby producing a pro-
diversification, it was necessary to inactivate the aM-IIcessed hybrid that is also the specific substrate of
gene in the mouse germline. We report that mice lackingGlcNAc-TII (Harpaz and Schachter, 1980; Tulsiani et al.,
a functional aM-II allele develop a dyserythropoietic1982; Moremen et al., 1994; Figure 1). This role is further
anemia similar to CDA type II, with production of abnor-supported from studies of the Ric15 BHK cell line, in
mal erythrocytes lacking complex N-glycans. Unexpect-which a reduction in aM-II activity occurs with an attenu-
edly, complex N-glycan production continued amongation of complex N-glycan production (Hughes and
nonerythroid cell types in the absence of aM-II activityFeeney, 1986). An exogenous inhibitor of aM-II activity
known as swainsonine is found in plants of the genus by an alternate biosynthetic pathway.
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Figure 1. Asparagine-Linked Oligosaccharide Biosynthesis
The depicted oligosaccharide precursor is transferred from lipid to asparagines on nascent peptides in the endoplasmic reticulum prior to
glucosidase and a1±2 mannosidase trimming. In the medial Golgi, Mgat1-encoded GlcNAc-TI initiates hybrid N-glycan synthesis. Conversion
to complex N-glycans requires a-mannosidase-II to generate the processed hybrid N-glycan that is also the substrate of GlcNAc-TII. Anomeric
linkage types are denoted. Closed triangles represent glucose; open circles, mannose; closed squares, N-acetylglucosamine. Addition of
fucose (open triangle) may occur earlier than indicated. Multi-antennary complex N-glycans result from other branching reactions (arrows).
Results GlcNAc1Man3GlcNAc-PA, but was absent from extracts
derived from aMIID/aM-IID mice or extracts treated with
swainsonine (Figures 3A and 3B; data not shown). Addi-aM-II Gene Inactivation in Embryonic Stem
Cells and Mice tionally, an antibody specific for aM-II failed to immuno-
precipitate aM-II activity from total cell extracts derivedaM-II is a type II transmembrane protein of 1150 amino
acids encoded by a single gene locus in studied verte- from aMIID/aM-IID samples (data not shown). These ex-
periments demonstrated that the exon deletion pro-brates (Moremen and Robbins, 1991; Moremen et al.,
1994). A mouse genomic clone that contained an exon duced in the aM-II gene (aM-IID) results in a complete
loss of enzyme activity and is thus a genetic null allele.representing a portion of the lumenal ªstemº domain of
aM-II was isolated. As sequence analysis indicated that
excision of this exon would create a translational
frameshift mutation, a gene targeting construct was pro- Mice Lacking a Functional aM-II Allele
Exhibit Splenomegaly Associatedduced that would permit excision of this exon and re-
moval of the marker genes by Cre recombinase (Figure with Dyserythropoietic Anemia
Mice lacking a functional aM-II allele did not display2A; reviewed in Marth, 1996). G418 resistant embryonic
stem cell clones were analyzed for homologous recom- noticable neurologic or behavioral symptoms and bred
normally with either wild-type or homozygous-null mates.bination events, producing a modified aM-II locus bear-
ing three loxP sites as required to produce systemic Histologic findings of the liver, brain, kidney, lymph
nodes, heart, lung, and pancreas were unremarkable.(D) and conditional (F) mutations (Figures 2B and 2C).
Chimeric mice generated from ES clones 34±107 and Leukocyte development, morphology, circulation, and
colonization of secondary lymphoid organs also ap-31±107 were bred to C57BL/6 mates to produce mice
heterozygous for aM-IID or aM-IIF alleles, respectively. peared normal in aM-II-deficient mice (data not shown).
However, analyses of peripheral blood indicated highOffspring homozygous for either allele were obtained at
normal frequencies, and those bearing aM-IID alleles levels of reticulocytes and significant variations in eryth-
rocyte cell size (anisocytosis) (Figure 4A).aM-II-deficientwere further analyzed.
mice of all ages invariably exhibited a marked spleno-
megaly (Figure 4B). Additionally, detailed hematologicMice Homozygous for the aM-IID Allele Lack
aM-II Enzyme Activity analyses revealed a mild-to-moderate anemia, accom-
panied by a marked anisocytosis, reduced osmotic fra-aM-II activity can be specifically determined using the
fluorescent substrate GlcNAc1Man5GlcNAc-pyridylam- gility, indicating a likely increase in the surface area
to volume ratio, reticulocytosis involving up to 30% ofine (-PA). Release of mannose alters the chromato-
graphic mobility of this molecule in a defined manner. circulating red blood cells, and increased levels of the
i-antigen (Figures 4C-4G). The aM-II-null bone marrowaM-II has been immunolocalized to theearly Golgi appa-
ratus in most cell types (Moremen et al., 1994), and Golgi exhibited normal cellularity but an increase in erythro-
blasts (Figure 4H). Anisocytosis, reduced osmotic fragil-fractions from genotyped mouse tissues were examined
for aM-II activity by a 2 to 24 hr incubation with substrate ity, increased i-antigen levels, and erythroblast hyper-
plasia were observed in aM-II-null mice of all ages,in thepresence or absence of swainsonine. aM-II activity
was present in wild-type samples with the generation whereas the severity of the anemia and reticulocytosis
increased with age.of the cleaved products GlcNAc1Man4GlcNAc-PA and
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1992). This binding requires the action of GlcNAc-TII,
which cannot occur without aM-II (Figure 1). In wild-
type erythrocytes, at least six glycoproteins bearing
complex N-linked oligosaccharides were visualized by
E-PHA binding (Figure 5A, right panel). This binding was
absent from mutant samples, indicating that aM-II defi-
ciency abrogates the production of complex N-glycans
in erythrocytes. Mouse erythrocyte glycoproteins bear-
ing complex N-linked oligosaccharides appeared upon
close inspection to be distinct from those observed by
Coomassie blue.
Erythroid Cells from aM-II-Null Mice Are Uniquely
Deficient in Complex N-Glycans
Unexpectedly, analyses of various hematopoietic cells
with E-PHA-biotin revealed that only erythocytes were
deficient in complex N-glycans (Figure 5B).Thymocytes,
myeloid cells, and mature lymphocytes displayed es-
sentially normal levels of E-PHA binding, while erythro-
blast cell surfaces in the bone marrow were variably
deficient. O-glycosylation appeared unaffected, as
expected (Figure 5C); however, E-PHA histochemistry
of the liver, kidney, spleen, pancreas, epidermis, and
brain also indicated a normal level of cell surface com-
plex N-glycans on aM-II-null cells (data not shown). Sur-
prisingly, congenital loss of aM-II function appeared to
ablate complex N-glycan production specifically in the
erythroid lineage. This implied that an undisclosed alter-
nate biosynthetic pathway was operating in other cell
types. The nature of this alternate pathway was investi-
gated by analyzing N-linked oligosaccharide biosynthe-
sis and structural diversity in aM-II-deficient cells that
retained E-PHA binding.
Figure 2. aM-II Gene Mutagenesis in Embryonic Stem Cells and
Mice
(A) A mouse genomic clone of aM-II bearing a single exon (closed Structural Analyses of N-Glycan Biosynthesis
box) was isolated and used in constructing the aM-II gene targeting in the Absence of aM-II
vector with pflox as indicated. Homologous recombination with wild-
Splenocytes and primary fibroblasts were metabolicallytype embryonic stem cells (R1) generates the F[tk-neo] allele.
labeled with glucosamine or mannose for various times(B) Transient Cre recombinase expression and ganciclovir selection
prior to isolating N-linked oligosaccharides for structuralwill result in ES subclones bearing aM-IID (systemic-null) and aM-IIF
(conditional-null) alleles. studies, using chromatography and exoglycosidase di-
(C) Genomic Southern blotting confirmed the expected aM-II allelic gestions. Complex N-glycan production in the absence
structures. Upper left: targeted ES clones 107 and 258 harbored the of aM-II could occur from an altered lipid-linked oligo-
7.5 kb (F[tk-neo]) allele and the 6.5 kb wild-type (wt) allele. Upper
saccharide precursor lacking four mannose residuesright: clone 107 bearing all three loxP sites was used in producing
normally added by Dol-P-Man (Stoll et al., 1982). How-cells bearing aM-IIF (31±107) and aM-IID (34±107) alleles. Lower
ever, HPLC analyses did not reveal such an alteredpanel: mice heterozygous and homozygous for the 6.5 kb aM-IID
allele are shown from Southern blot analyses of tail DNA. One- precursor in aM-II-deficient cells (Figure 6A). Newly syn-
kilobase molecular weight ladders are in left lanes of above. Restric- thesized oligosaccharide precursors are sometimes
tion enzyme sites Sma, SmaI; B, BamHI; K, KpnI; S, SacI; X, XbaI rapidly cleaved intact from lipid and protein; however,
are denoted.
the proportion and size of those liberated during the
labeling were also the same in control and mutant cells
(data not shown). These results indicate that aM-II-nullComplex N-Glycan Deficiency in Mutant
Erythrocyte Membranes cells synthesize a normal lipid-linked oligosaccharide
precursor and transfer this to protein as efficiently asA normal profile of membrane-associated and cytoskel-
etal proteins was observed in aM-II-deficient erythro- wild-type cells.
ConA affinity chromatography is useful in determiningcytes by SDS-PAGE and Coomassie blue staining, indi-
cating that no changes occurred in the expression of the proportion of tetra-, tri- and biantennary complex,
hybrid, and high mannose N-linked oligosaccharidesthe major membrane constituents (Figure 5A, left panel).
Glycoproteins bearing complex N-linked oligosaccha- (Baenziger and Fiete, 1979; Narasimhan et al., 1979).
Surprisingly, aM-II-deficient cells containedN-linked oli-rides can be directly demonstrated by binding to the
lectin E-PHA (Yamashita et al., 1983; Kobata and Endo, gosaccharides that eluted with the ConA-Sepharose
Cell
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Figure 3. Absence of aM-II Activity in Mice
Homozygous for the aM-IID Allele
(A) HPLC profile following 4 or 24 hr incu-
bation of GlcNAc1Man5GlcNAc-PA with micro-
somal spleen membrane extracts, demon-
strating no detectable processing in the
aM-IID/aM-IID sample (lower panel). Retention
time of oligosaccharide standards are indi-
cated at the top of each panel: 3, GlcNAc1-
Man3GlcNAc-PA; 4, GlcNAc1Man4GlcNAc-PA;
5, GlcNAc1Man5GlcNAc-PA.
(B) Spleen, liver, and kidney derived from aM-
IID/aM-IID mice lacked aM-II activity. Shown
are specific activity measurements after incu-
bation with GlcNAc1Man5GlcNAc-PA for 24 hr
as in (A). The rate of mannose cleavage was
determined in the linear range of the cleavage
assay and calculated as a percentage of the
total susceptible mannose residues cleaved per hour. Shown are mean values and SEM from three separate comparative experiments with
individual animals.
flowthrough and in response to 10 mM a-methyl gluco- enzyme was predicted to be specific for Man5GlcNAc2-
Asn, generating Man3GlcNAc2-Asn, which is also a sub-side, as characteristic of complex forms. These were,
however, distinctly underrepresented in aM-II-deficient strate for GlcNAc-TI from in vitro studies (Schachter,
1986, 1991). We therefore tested Golgi and microsomalextracts (Figure 6B, peaks a, b, e, and f; data not shown).
The proportion of high mannose N-glycans was unal- fractions of various cell types for the presence of this
aM activity.tered, and hybrid N-glycans were significantly increased
as expected (Figure 6B, peaks c, d, g, and h). An aM activity toward Man5GlcNAc-PA was found in
all mouse cell and tissue types tested, including spleno-To resolve further the N-linked oligosaccharide spe-
cies separated by ConA-Sepharose chromatography, cytes, liver, kidney, and primary fibroblasts. This enzyme
activity (termed aM-III) was optimal at pH 6.0±6.5 and,fractions were desialylated and analyzed by HPLC (Fig-
ure 6C). Among those that eluted with 10 mM a-methyl- in the presence of Co21, generated Man4GlcNAc-PA,
Man3GlcNAc-PA, and even Man2GlcNAc-PA and Man1-mannosidase, the abundance in peak 7 was greatly ele-
vated with aM-II deficiency. Exoglycosidase studies of GlcNAc-PA at later time points (Figure 7 and data not
shown). No change in aM-III activity was observedpeak 7 confirmed that this was a hybrid-type N-linked
oligosaccharide species (Figure 6C legend; Experimen- among aM-II-deficient cells. aM-III activity in the mouse
appeared identical to an aM activity previously discov-tal Procedures). Similar analyses of putative complex
N-linked oligosaccharides previously eluted with 10 mM ered in the rat liver (Bonay and Hughes, 1991; Bonay et
al., 1992) and was also greatly enriched in Golgi anda-methyl-glucoside (Figure 6C, panels b and f, peak 2)
revealed the standard biantennary complex oligosac- microsomal preparations. A revision to theN-glycan bio-
synthetic pathway was therefore indicated, in whichcharide NA2 (Experimental Procedures). The bianten-
nary complex N-linked oligosaccharide in HPLC peak 2 complex N-linked oligosaccharides are produced by
two mutually exclusive routes (Figure 8).was also confirmed by sequential exoglycosidase di-
gestion to harbor the trimannosyl core (Figure 6D, left
panels). Complex N-linked oligosaccharides bearing the Discussion
trimannosyl core were similarly revealed among aM-II-
deficient primary fibroblasts (Figure 6D, right panels). Alpha-Mannosidase Function in Complex
These studies indicated that loss of aM-II activity did N-Glycan Biosynthesis
not alter levels of high mannose N-glycans but resulted Our findings are consistent with aM-II acting specifically
in a 3-fold increase in the abundance of hybrid N-gly- to process the GlcNAc1Man5GlcNAc2-Asn hybrid during
cans. Surprisingly, complex N-glycans were present in N-glycan biosynthesis. In the absence of aM-II, this hy-
aM-II-deficient cells at approximately 50% the level brid N-glycan is modified by Golgi b1±4 galactosyltrans-
found in wild-type cells and at apparently normal levels ferase prior to a 3-fold accumulation observed in spleno-
on the cell surface (Table 1; Figure 5B). cytes and primary fibroblasts. Unexpectedly, complex
N-glycans were found at approximately 50% of normal
total cellular levels among aM-II-deficient splenocytesAn Alternate Pathway to Complex
N-Glycan Production and fibroblasts. The initial rate of conversion to complex
N-glycans was found to be unchanged, and little or noThe synthesis of complex N-glycans as determined
above in aM-II-deficient cells was not compatible with complex N-glycan deficiency could be detected on the
cell surface. aM-II-null cells generated complex N-linkedthe previously defined biosynthetic pathway. To explain
these results, it was necessary to invoke the presence oligosaccharides bearing the trimannosyl core originat-
ing from an unaltered dolichol oligosaccharide precur-of a distinct aM that functions early in N-glycan biosyn-
thesis. Moreover, given the well-defined substrate spec- sor. These observations indicated the presence of a
distinct aM activity functioning in an alternate pathwayificities of GlcNAc-TI and GlcNAc-TII, this distinct aM
Oligosaccharide Biosynthesis and Function
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Figure 4. Dyserythropoietic Anemia in aM-II-
Null Mice
(A) Peripheral blood smear stained with
Wright-Giemsa from an aM-II-null mouse re-
veals erythrocyte cell size heterogeneity (ani-
socytosis) and ªstressº reticulocytes (arrow).
(B) Splenomegaly was found in all aM-II-defi-
cient mice (n 5 12).
(C) Absence of aM-II resulted in a mild-to-
moderate anemia.
(D) Red cell distribution width (RDW) was in-
creased in aM-II-null mice, confirming the an-
isocytosis apparent in blood smears.
(E) Osmotic fragility was reduced in the ab-
sence of aM-II.
(F) Reticulocyte levels were elevated in aM-
II-null mice, as detected using new methylene
blue.
(G) Increased i-antigen in aM-II deficiency.
Erythrocytes of either genotype failed to ag-
glutinate with a 1/120 dilution of anti-I anti-
sera; however, anti-i antisera agglutinated
aM-II-null erythrocytes at a 1/3840 dilution
as compared with a 1/480 dilution required
for wild-type erythrocytes. Agglutination re-
sponse to anti-i antisera was defined as the
maximum-fold reduction in antibody titer that
continued to produce erythrocyte agglutina-
tion (n 5 3).
(H) Erythroblast frequencies in the spleen and
bone marrow were increased in aM-II-null
mice (n 5 12).
Mean values are denoted by horizontal bars.
Standard deviations from the mean are
shown by vertical bars. All mice were 6 weeks
of age or older and analyzed with littermate
genotypic controls. Each point in (C), (D), and
(F) represents a result from an individual ani-
mal. Littermate controls were included.
in complex N-glycan biosynthesis. They may also indi- to complex N-glycan production hence includes a rela-
tively swainsonine-resistant aM-III activity, functioningcate a low turnover rate for complex N-glycans at the
cell surface, variable transport rates to the plasma mem- independently and exclusive of aM-II (Figure 8). This
revised pathway isalso consistent with the lack of hybridbrane, and recycling mechanisms from the membrane
allowing further oligosaccharide maturation. and complex N-glycans with GlcNAc-TI deficiency (Ioffe
and Stanley, 1994; Metzler et al., 1994). The previousAn aM activityacting onMan5GlcNAc-PA and generat-
ing Man3GlcNAc-PA (termed aM-III) was found among unavailability of cells bearing aM-II-null alleles in combi-
nation with the cation dependence of aM-III activity inall mouse tissues surveyed and at levels comparable to
wild-type and aM-II-null cells. aM-III activity in the vitro may explain why the alternate pathway was not
revealed in earlier studies.mouse did not act on hybrid structures, including
GlcNAcMan5GlcNAc-PA in the presence of Co21, and
exhibited a reduced sensitivity to inhibition by swainso-
nine when compared with aM-II (data not shown). Re- Dyserythropoiesis in Murine aM-II Deficiency
and Relevance to Human CDA type IIgarding swainsonine inhibition of N-glycan biosynthe-
sis, such studies have often reported finding various Erythroid cells are uniquely susceptible to alterations in
N-linked oligosaccharide biosynthesis evoked by aM-IIlevels of complex N-glycans remaining. Our analyses of
aM-II-deficient mice suggest that swainsonine-induced deficiency. This susceptibility arises from the apparent
absence of an alternate pathway in complex N-glycanlocoism with behavioral abnormalities, male sterility,
and cellular vacuolation is not a result of aM-II inhibition. production. Loss of complex N-linked oligosaccharides
and other membrane-bound constituents can lead toInstead,swainsonine likely induces these effects by inhi-
bition of the lysosomal a-mannosidase and perhaps defects involving ion transport, glycoprotein clustering,
membrane fluidity, and cytoskeletal stability (Fukuda,other aM enzymes, depending upon the plasma levels
of swainsonine attained in vivo. The alternate pathway 1993; Palek, 1995; Peters et al., 1996). An increase in
Cell
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Figure 5. Erythrocyte Membranes from aM-
II-Null Mice Are Uniquely Deficient in Com-
plex N-Glycans
(A, left panel) Major membrane and cytoskel-
etal components (erythrocyte ªbandsº) were
visualized by SDS-PAGE and Coomassie blue
staining. Using an alternate electrophoretic
method (Fairbanks et al., 1971), no changes
were observed in ankyrin expression in aM-
II-null samples (data not shown).
(A, right panel)Complex N-glycans are visual-
ized in wild-type samples but are absent from
mutant membranes.
(B) E-PHA-biotin and antibody-FITC conju-
gates specific for cell lineage and differentia-
tion antigens were combined in two-channel
fluorescent-activated cell sorting analyses
(Experimental Procedures). Among hemato-
poietic cell types from aM-II-null mice, circu-
lating erythrocytes (RBCs) lacked significant
binding to E-PHA, and bone marrow erythro-
blasts variably displayed a reduced level of
E-PHA binding.
(C) O-glycosylation as judged by Jacalin lec-
tin binding was unaltered among the indi-
cated cell types as wild-type and mutant
FACS profiles overlapped.
exposed mannose residues at the cell surface in aM-II- bases are yet unresolved (Beutler, 1995). aM-II-deficient
mice exhibit significant phenotypic similarities with hu-deficient mice may also target erythrocytes for interac-
tion with the mannose-receptor and macrophage en- man CDA type II. Splenomegaly with increased marrow
erythroblasts are common to both human and mousegulfment within the spleen. In comparison with human
erythrocyte glycoproteins known to contain complex syndromes, as are thevariable severityof anemia, aniso-
cytosis, and increased i-antigen levels. In CDA type II,N-linked oligosaccharides, mouse versions appear dis-
tinct and do not produce complex N-linked oligosaccha- the increase in i-antigen levels occurs on glycolipids. In
analyses of erythrocyte glycolipid structures from aM-rides on band 3. However, human and mouse glycopho-
rin A may normally contain high levels of sialic acid on II-null mice, we observed a similar increase in those
containing the endo-b-galactosidase sensitive i-antigencomplex N-linked oligosaccharide termini (Angel et al.,
1991). Absence of complex N-linked oligosaccharides polylactosamine (data not shown). Since normal mouse
erythrocytes display low levels of I- and i-antigens,may yield glycoproteins that are hypomorphic, dysfunc-
tional, or destabilized and perhaps absent from the i-antigen induction may reflect a decreased erythroid
maturation time common to the dyserythropoietic mar-membrane. Multiple targets as potential phenotypic ef-
fectors commonly arise in studies of enzyme deficien- row (Beutler, 1995). Glycosylation abnormalities in CDA
type II otherwise occur in a manner that would be ex-cies. Likewise, identification of altered glycoproteins in
aM-II-deficient erythrocytes will be relevant in defining pected for aberrant N-glycan production with deficiency
of aM-II, GlcNAc-TII, or a galactosyltransferase (Fukudathe inductive events that precipitate dyserythropoietic
anemia. et al., 1987, 1989, 1990). Nevertheless, lack of familial
genetic data and the presence of normal aM-II levels inThe human CDAs comprise a heterogenic group of
three clinically defined anemias for which the genetic all but one case reported thus far calls into question the
Oligosaccharide Biosynthesis and Function
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Figure 6. Complex N-linked Oligosaccharides Produced in the Absence of aM-II
Oligosaccharides from splenocytes and primary fibroblasts were metabolically labeled and analyzed as described (Experimental Procedures).
(A) Fibroblast-derived lipid-linked precursor and nascent protein-linked N-glycans migrated with a normal-sized oligosaccharide precursor
(right arrow) and not with a truncated precursor produced in the absence of Dol-P-Man (left arrow).
(B) ConA-affinity chromatographic separation of splenocyte N-linked oligosaccharides. Tetra- and triantennary complex N-linked oligosaccha-
rides are enriched in flow-through fractions and found in both genotypic samples (a and e). Biantennary complex N-linked oligosaccharides
eluting with 10 mM a-methyl-glucoside (1) were present but in reduced abundance in aM-II-null cells (b and f). Hybrid N-linked oligosaccharides
eluting with 10 mM a-methyl-mannoside (2) were increased in aM-II-deficient cells (compare c and g). The proportion of high mannose
oligosaccharides eluting with 0.2 M a-methyl-mannoside appeared unchanged (d and h). Similar results were obtained with primary fibroblasts
(data not shown).
(C) HPLC resolution of splenocyte oligosaccharides separated by ConA-Sepharose affinity chromatography. Hybrid N-glycan (peak 7) was
increased in aM-II-deficient splenocytes and was defined by exoglycosidase treatment as the structure: Galb1±4GlcNAcb1±2Mana1±3[Mana1±
3(Mana1±6)Man a1±6]Manb1±4Glc NAcb1±2GlcNAc (data not shown). HPLC fractions were also collected corresponding to tetra- and trianten-
nary (a, e; peak 1) and biantennary (b, f; peak 2) N-linked oligosaccharides. The N-linked oligosaccharide in peak 2 comigrated with a
bianntenary complex oligosaccharide standard (arrow).
(D, left) Sequential exoglycosidase treatment was applied to the N-linked oligosaccharide in HPLC peak 2. Studies confirmed the standard
biantennary structure including the trimannosyl core (M3G2: Mana1±3[Mana1±6]Manb1±4GlcNAcb1±4GlcNAc). Position of released, labeled
GlcNAc is indicated as is the original mobility of peak 2.
(D, right) Identical results were obtained using primary fibroblasts. Brackets denote elution position of undigested oligosaccharides derived
from 10 mM a-methyl glucoside-eluted ConA-Sepharose fractions (data not shown). Elution position of M3G2 standard is indicated (asterisk).
role of aM-II mutation in most instances of human CDA of the endoplasmic reticulum in some CDA type II eryth-
rocytes (Fukuda, 1993). Neither was there hepatomeg-type II.
Significant differences appear between CDA type II aly, liver cirrhosis, or hemosiderosis. It is possible that
these phenotypic variations reflect species-specific gly-and mouse aM-II deficiency. No evidence for multinucle-
ated erythroblasts could be found in the aM-II-deficient cosylation functions, or perhaps the genetic heteroge-
neity of human CDA type II. Whatever the reasons formouse bone marrow, although these are commonly
found in marrow from CDA type II patients. Moreover, the reported differences, our results indicate that loss
of aM-II gene function is one genetic basis for congenitalelectron microscopic analyses did not detect the ªdou-
ble membraneº effect that may reflect incomplete loss dyserythropoietic anemia.
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complex N-glycan levels, suggesting that aM-III activityTable 1. Percent Abundance of N-linked Oligosaccharide
functions both initially and at high efficiency in catalyzingStructures in Splenocytes and Primary Fibroblasts
from Wild-Type and aM-II-Null Mice the conversion to complex N-glycans. It is possible that
GlcNAc-TI competes with aM-III for the Man5GlcNAc2-N-Linked Oligosaccharides Wild-Type aM-II-Null
Asn N-glycan, perhaps leading to a difference in the
Splenocytes repertoire of N-glycans on some aM-II-deficient nonery-
High mannose 31.9 26.1
throid cells. aM-II may also be compensatory in someHybrid 17.4 51.1
situations of aM-III deficiency. Such an apparent redun-Complex 50.7 22.8
dancy is actually advantageous, since vertebrates lack-
Primary Fibroblasts
ing complex N-glycans from GlcNAc-TII-deficiency areHigh mannose 47.5 48.5
severely impaired with neurologic and developmentalHybrid 12.5 35.0
complications, leading to lethality prior to reproductiveComplex 40.0 16.5
age (Jaeken et al., 1994; Tan et al., 1996; R. Campbell
Amount of radiolabeled N-linked oligosaccharides residing in ConA-
and J. M., unpublished data). The aM-II-deficient mouseSepharose fractions (Figure 6B) calculated as a percentage of to-
has provided intriguing questions to be considered intal cpm.
revealing an alternate pathway in N-glycan biosynthesis,
without which erythroid complex N-glycan production
fails and dyserythropoietic anemia ensues.
The Alternate Pathway to Complex N-Glycan
Production in Normal and Experimental Procedures
Disease Physiology
The alternate pathway in complex N-glycan biosynthe- Production of Targeted Embryonic Stem Cell Lines
and aM-II-Deficient Micesis provides a mechanism to compensate for the ab-
The mouse aM-II cDNA (Moremen and Robbins, 1991) was used tosence of aM-II. Nevertheless, erythroid cells cannot
isolate a 17 kb mouse genomic aM-II clone from a 129/SvJ library
compensate for aM-II deficiency, and this appears to (Stratagene) by cross-hybridization as previously described (Priatel,
explain the cell-type specificity of the phenotype ob- 1997). Sequence analysis revealed a single aM-II exon correspond-
served. Why the alternate pathway does not seemingly ing to amino acids 236±258. Construction of an aM-II gene-targeting
vector was accomplished using the pflox vector (Figure 2A). Thefunction in erythroid cells requires additional investiga-
linearized aM-II-targeting DNA construct (10 mg) was introducedtion. It is possible that aM-III is simply not expressed in
into R1 ES cells via electroporation, prior to selection with 150 mg/
erythroblasts or exists in an inactivated form. Alterna- ml of active G418 (Life Technologies) for 10 days on gelatin-coated
tively, aM-III may be relatively labile, with loss of cofac- tissue culture dishes as described (Priatel et al., 1997). PCR positive
tors occurring early in erythrocyte maturation and prior clones were analyzed using an aM-II genomic probe consisting of
a 1.1 kb SmaI-XbaI fragment as denoted (Figure 2A). The loxP probeto enucleation. Characterization of the gene(s) responsi-
consisted of two loxP sites separated by plasmid multiple-cloningble for encoding aM-III activity is needed to address
sites (Hennet et al., 1995). ES cell clones bearing a targeted aM-IIthese issues. In this regard, recent analyses of a human allele were electroporated with 10 mg of supercoiled Cre expression
gene product termed aM-IIx (Misago et al., 1995) have plasmid pCre-Hygro and plated at low dilution. After 4 days, gan-
revealed that the encoded aM enzyme is located in the ciclovir (2 3 106 M) was added, and, 5 days later, resistant subclones
were analyzed by Southern blotting. Chimeric mice were producedcis Golgi and acts on Man5GlcNAc22 toproduce Man3Gl-
by microinjection of 8±10 clonal ES cells into3.5 day C57BL/6 blasto-cNAc22 (M. N. F., unpublished data). Whether human
cyst-stage embryos, followed by implantation as described (MetzleraM-IIx is the homolog of the gene encoding aM-III activ-
et al., 1994). The altered aM-II allele was crossed into the C57BL/6
ity in the mouse is unclear, as aM-IIx activity does not background for the production of heterozygous aM-II mutant mice
appear to be dependent upon Co21. Multiple aM en- and bred with C57BL/6 mates for at least three to five generations.
Homozygous aM-IID mice and littermate control animals used in thiszymes that process Man5GlcNAc2-Asn may exist; alter-
study were generated by crosses involving these aM-IID heterozy-natively, rodent and human aM-IIx may be orthologous
gotes.with different enzymatic properties arising from signifi-
cant structural divergence. aM-II and aM-III Enzymatic Analyses
Among nonerythroid cells studied in aM-II-deficient Mouse tissues were homogenized in 1±2 ml of extraction buffer (2%
Triton X-100, 0.5 M NaCl, 20 mM potassium phosphate [pH 7.5]),mice, these harbored approximately 50% of normal
Figure 7. Presence of a Distinct aM Activity
Processing Man5GlcNAc-PA in Golgi and Mi-
crosomal Preparations from Normal and aM-
II-Deficient Cells
(A) Splenocyte microsomal fractions exhib-
ited an aM-processing activity toward Man5-
GlcNAc-PA (5) yielding Man4GlcNAc-PA (4),
Man3GlcNAc-PA (3), and Man2GlcNAc-PA (2)
by 24 hr (Experimental Procedures).
(B) This aM activity was also observed at sim-
ilar levels in Golgi fractions of liver and kidney
from wild-type and aM-II-null mice.
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Figure 8. Proposed Revision in the Biosynthetic Pathway of Complex Asparagine-Linked Oligosaccharide Production
The aM-III designation is a tentative nomenclature based upon the differences in aM-I and aM-II activities previously defined within the
N-glycan processing pathway. The Co21-activated aM previously described (Bonay and Hughes, 1991; Bonay et al., 1992) is a likely candidate
for the aM-III activity detected herein among Golgi and microsomal fractions, although it is not presently possible to rule out the existence
of multiple isozymes.
centrifuged at 16,000 3 g for 5 min, and assayed for aM activity with were labeled in a final volume of 100 ml with either fluorescein (FITC)-
pNP-Man and GlcNAc1Man5GlcNAc1-PA substrates as total cellular conjugated E-PHA (1 mg/ml) or Jacalin-FITC (0.5 mg/ml) (Vector Lab-
supernatants, or as immunoprecipitates using 2 ml anti-Man II anti- oratories). Subsequently, cells were incubated with 1 ml of indicated
serum (Moremen et al., 1991; Liao et al., 1996). Microsomes and antibody for 10 min. All incubations and washes were performed
Golgi membranes were prepared as previously described (Moremen on ice in FACS buffer (2% FCS in PBS). Cells were analyzed using
and Touster, 1986) and stored at 2208C prior to analyses with a FACScan Flow Cytometer and CellQuest Software (Becton Dickin-
GlcNAc1Man5GlcNAc-PA and Man5GlcNAc-PA as substrates in 100 son, Mountain View, CA) as previously described (Hennet et al.,
mM NaAc (pH 5.6) and 100 mM N-acetylglucosamine, or in 100 1995). Lineage-specific antibodies included erythroid phycoerythrin
mM NaAc (pH 6.5), 100 mM N-acetylglucosamine, and 1 mM CoCl2 (PE)-conjugated TER-119, myeloid anti-Ly-6G-PE (Gr-1, RB6-8C5),
(Bonay and Hughes, 1991; Liao et al., 1996; Merkle et al., 1997). In B lymphoid anti-B220-PE (RA3-6B2), and T lymphoid anti-CD3-PE
all assays, sensitivity to inhibition by swainsonine was tested using (145-2C11) (Pharmingen).
a 10 mM final concentration of the alkaloid. GlcNAc1Man5GlcNAc
and Man5GlcNAc werekindly provided by Dr. Jeremy Carver (Univer-
sity of Toronto) and by Dr. Annette Herscovics (McGill Cancer Cen- Asparagine-Linked Oligosaccharide Characterization
ter, Montreal), respectively. Tail biopsy-derived primary fibroblasts were labeled in 5.5 mM glu-
cose DMEM with 20 mCi/ml [2-3H]mannose for 24 hr. Preparation of
Hematology and Histology 3H-mannose-labeled oligosaccharides hydrolyzed from precursor
Mice were anesthetized with methoxyfluorane, and blood was col- lipid or from protein by PNGaseF digestion was as described
lected from the tail vein into EDTA-coated polypropylene tubes (Bec- (Sampath et al., 1992; Panneerselvam and Freeze, 1996). Spleno-
ton Dickinson). A CELL-DYN 3500 programmed for normal mouse cytes were labeled with 20 mCi/ml 3H-glucosamine for 24 hr in 98%
parameters was used to assess cellular size, volume, and morphol- glucose-deficient medium with 2% normal RPMI 1640 and 10%
ogy involving red blood cells, leukocytes, and platelets as described dialyzed fetal calf serum. Glycoproteins were extracted with 0.5%
(Priatel et al., 1997). Parallel blood smears were performed and Triton X-100 in 0.1 M Tris-HCl (pH 6.8) containing 0.1 M NaCl, 0.3 M
stained with Wright-Giemsa solution or new methylene blue (for
sucrose, 3 mM MgCl2, 1 mM PMSF, and digested with PNGaseF.reticulocyte counts) for manual analyses. Osmotic fragility measured
Released N-linked oligosaccharides were reduced to alditols with
percent hemolysisby OD540 inresponse to indicated NaClconcentra- 1 M NaBH4 and applied to 1 3 4 cm ConA Sepharose columnstions. Levels of RBC Ii-antigens were defined with antisera pre-
equilibrated in 10 mM Tris-HCl (pH 7.5). Oligosaccharides wereviously described (Feizi et al., 1979; Hakomori et al., 1981). Anti-I
eluted sequentially with 10 mM a-methyl glucoside, 10 mM a-methylor anti-i antisera was serially diluted with PBS in a round-bottom
mannoside, and 0.2 M a-methyl mannoside. Radioactivity wasmicrotiter plate. RBCs from wild-type or aM-II-null mice were added
monitored in 1 ml fractions produced. Oligosaccharide-alditols re-to each well and incubated on ice for 4 hr, after which the presence
solved by ConA-Sepharose chromatography were desialyated byor absence of hemagglutination was assessed.
mild acidhydrolysis and analyzedby ion suppression amine adsorp-Histologic studies were performed on paraffin or frozen tissue
tion (ISAA)/HPLC using a Varian MicroPak AX-5 column. Standardsections by methods previously described (Campbell et al., 1995).
high mannose-type oligosaccharides, M9, M8, M7, M6, M5, and aStaining and lectin reagents included hematoxylin/eosin, Oil red O,
biantennary complex type oligosaccharide, NA2 (Galb1±4GlcNAcb1±Sudan black, iron (Perls reaction), and lectins E-PHA, ConA, Jacalin,
2Mana1±3[Galb1±4GlcNAcb1±2Mana1±6]Manb1±4GlcNAcb1±4Glcand L-PHA (Vector Laboratories).
NAcOH), were purchased from Oxford Glycosystems (Oxford, U.
K.). M3G2 (Mana1±3[Mana1±6]Manb1±4GlcNAcb1±4GlcNAcOH) wasFlow Cytometric Analyses
prepared from NA2 by exoglycosidase digestion. ConA-Sepha-Single cell suspensions were isolated from mice and subjected to
rose- and HPLC-separated oligosaccharides were exoglycosidasehypotonic lysis of red blood cells, using ammonium chloride when
indicated. Cells were counted using a hemocytometer, and 500,000 treated as described (Merkle and Cummings, 1987).
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RBC Protein, Glycoprotein, and Glycolipid Analyses lysis test; a typical congenital dyserythropoietic anaemia. Br. J.
Haematol. 17, 11±26.Erythrocyte membranes were prepared and analyzed by SDS-PAGE
as previously described (Fairbanks et al., 1971; Fukuda et al., 1984). Dorling, P.R., Huxtable, C.R., and Vogel, P. (1978). Lysosomal stor-
In other studies, intact erythrocytes were labeled with NaB[3H]4 to age in swainsona spp. toxicosis: an induced mannosidosis. Neuro-
incorporate tritium on nonreducing terminal galactose and N-acetyl- path. Appl. Neurobiol. 4, 285±295.
galactosamine residues in glycoproteins and glycolipids (Fukuda et Dorling, P.R., Huxtable, C.R., and Colgate, S.M. (1980). Inhibition of
al., 1979) prior to SDS-PAGE and autoradiography. For lectin blot- lysosomal a-mannosidase by swainsonine, an indolizidine alkaloid
ting, SDS-PAGE-resolved proteins were transferred onto nitrocellu- isolated from Swainsona canescens. Biochem. J. 191, 649±651.
lose and incubated in PBS-T (PBS containing 0.05% Tween-20)
Elbein, A.D., Solf, R., Dorling, P.R., and Vosbeck, K. (1981). Swain-supplemented with 3% BSA for 4 hr. Blots were subsequently incu-
sonine: an inhibitor of glycoprotein processing. Proc. Natl. Acad.bated with 2 mg/ml biotinylated E-PHA (Vector) for 1 hr at 258C,
Sci. USA 78, 7393±7397.washed three times in PBS-T, and incubatedwith avidin-horseradish
Fairbanks, G., Steck, T.L., and Wallach, D.F.H. (1971). Electropho-peroxidase for 30 min prior to development, using ECL as described
retic analysis of the major polypeptides of the human erythrocyte(Amersham). For glycolipid analyses, erythrocyte glycolipids were
membrane. Biochemistry 10, 2606±2617.extracted from NaB[3H]4-labeled membranes with chloroform meth-
Feizi, T., Childs, R.A., Watanabe, K., and Hakomori, S. (1979). Threeanol (2:1, v/v), analyzed by thin-layer chromatography on an HPTLC
types of blood group I specificity among monoclonal anti-I autoanti-silica gel plate (Baker, Si-HPF plate), and developed in a solvent
bodies revealed by analogues of a branched erythrocyte glycolipid.composed of chloroform, methanol, and water (60:35:8, v/v). Radio-
J. Exp. Med. 149, 975±980.active erythrocyte glycolipids were visualized by fluorography and
resolved in relation to the migration of glycolipid standards. Fukuda, M.N. (1993). Congenital dyserythropoietic anaemia type
II (HEMPAS) and its molecular basis. Baillieres Clin. Haematol. 6,
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